Stock Price Forecast
The 6 analysts offering 12-month price forecasts for Amyris Inc have a median target of 12.50, with a high estimate of 22.00 and a low estimate of 8.00. The median estimate represents a +175.94% increase from the last price of 4.53.
Similarly Why is Amyris stock so low? Failing to meet analysts’ top-line estimates, Amyris reported a 30% year-over-year decline in its ingredients business, to the chagrin of investors, and it seems as if the company will continue to face challenges in the fourth quarter.
Who owns AMRS stock? Top 10 Owners of Amyris Inc
| Stockholder | Stake | Total change |
|---|---|---|
| The Vanguard Group, Inc. | 5.35% | -2.42% |
| Farallon Capital Management LLC | 5.25% | +53.69% |
| BlackRock Fund Advisors | 3.40% | -11.54% |
| BlackRock Advisors LLC | 2.93% | -12.22% |
Additionally, Does Amyris pay dividends?
AMYRIS (NASDAQ: AMRS) does not pay a dividend.
Should I buy AMRS stock now?
Is Amyris a buy right now? 4 Wall Street equities research analysts have issued « buy, » « hold, » and « sell » ratings for Amyris in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should « buy » Amyris stock.
Is Amrs a good stock to buy now? Out of 4 analysts, 2 (50%) are recommending AMRS as a Strong Buy, 2 (50%) are recommending AMRS as a Buy, 0 (0%) are recommending AMRS as a Hold, 0 (0%) are recommending AMRS as a Sell, and 0 (0%) are recommending AMRS as a Strong Sell. What is AMRS’s earnings growth forecast for 2022-2024?
Is AMRS undervalued? Amyris (NASDAQ:AMRS) is undervalued given its current growth potential. The product pipeline works and will create disruptions in many ingredient segments.
Why did Amyris drop? While the major catalyst for the stock’s decline is the company’s uninspiring third-quarter 2021 earnings report, shareholders are also likely hitting the sell button in response to the company’s capital raise as well as Wall Street’s unfavorable take on the stock.
When did Amyris go public?
Amyris is registered under the ticker NASDAQ:AMRS . Their stock opened with $16.00 in its Sep 28, 2010 IPO.
Why did AMRS stock drop? Failing to meet analysts’ top-line estimates, Amyris reported a 30% year-over-year decline in its ingredients business, to the chagrin of investors, and it seems as if the company will continue to face challenges in the fourth quarter.
Is Amrs overvalued?
PB vs Industry: AMRS is overvalued based on its PB Ratio (5.8x) compared to the US Chemicals industry average (2.3x).
Is Amyris overvalued? The stock of Amyris (NAS:AMRS, 30-year Financials) is estimated to be significantly overvalued, according to GuruFocus Value calculation.
Is Zymergen publicly traded?
Zymergen Inc is a chemicals business based in the US. Zymergen shares (ZY) are listed on the NASDAQ and all prices are listed in US Dollars.
Is Ginkgo Bioworks publicly traded?
Ginkgo Bioworks — a Boston-based company that wants to make biology as easy to program as a computer — began trading on Friday after going public via a SPAC. Why it matters: Ginkgo’s multibillion-dollar offering is a milestone in the maturation of synthetic biology from a science to a true industry.
Is amyris a good company? Is Amyris a good company to work for? Amyris has an overall rating of 4.1 out of 5, based on over 246 reviews left anonymously by employees. 80% of employees would recommend working at Amyris to a friend and 68% have a positive outlook for the business. This rating has been stable over the past 12 months.
Who is Biossance owned by? On March 1, Amyris, which owns Biossance and children’s skin-care brand Pipette, announced it acquired clean luxury beauty brand Costa Brazil for an undisclosed sum and that founder Francisco Costa will become the chief creative officer of the parent company.
Does Biossance own Pipette?
Amyris was founded in 2003. The company owns three brands, Biossance and Pipette, for beauty and skincare, and Purecane, a sugar substitute.
What does Amyris Inc do? Amyris, Inc. produces and distributes chemical products. The Company serves the specialty and performance chemicals, flavors and fragrances, cosmetics ingredients, pharmaceuticals, and nutraceuticals markets.
Is Amyris good?
Amyris is a fast paced, challenging, and fun company to work for. The research and development is cutting edge and products are scaled-up and moved into manufacturing with impressive speed. Overall, the employees are very collaborative and work well in teams.
Is Amyris good stock to buy? Is Amyris stock A Buy? Several short-term signals are positive, despite the stock being in a falling trend, we conclude that the current level may hold a buying opportunity as there is a fair chance for stock to perform well in the short-term.
Should I invest in Zymergen?
Valuation metrics show that Zymergen Inc. may be overvalued. Its Value Score of F indicates it would be a bad pick for value investors. The financial health and growth prospects of ZY, demonstrate its potential to underperform the market.
Is Zymergen a good stock to buy? Zymergen has received a consensus rating of Hold. The company’s average rating score is 1.63, and is based on no buy ratings, 5 hold ratings, and 3 sell ratings.
Is Zymergen a good buy? Is Zymergen Stock a good buy in 2022, according to Wall Street analysts? The consensus among 7 Wall Street analysts covering (NASDAQ: ZY) stock is to Sell ZY stock.
Does Bill Gates own ginkgo bioworks?
Ginkgo Bioworks will make its market debut by merging with Soaring Eagle Acquisition Corp., the blank-check company led by former MGM CEO Harry Sloan.
Is Ginkgo Bioworks profitable?
Ginkgo’s cell programming platform generated about $34.7 million in revenue, up from $11.5 million during the same quarter in 2020. It works with companies to make engineered molecules for plant-based food, therapeutics, and cosmetics.
Who invested in ginkgo? Ginkgo’s proceeds come from a private placement of $775 million from investors — led by Baillie Gifford, Putnam Investments, and Morgan Stanley — and about $858 million from the Soaring Eagle trust account.